%fl\$#flZflZ\$# \$\Z#\$#°`""ı "\L!(&__\\/__\)



annual, fiscal 2019 to present

`(#fi(ŁŹł Ł`	20	023 ^{7.}	2022	2021		2020	2019
GAAP diluted earnings per share from continuing operations	\$	8.94 \$	5.98	\$ 14	.10 \$	8.64 \$	6.34
Adjustments							
Gain on Dermstore Sale	\$	- \$	_	\$ (0	.55) \$	- \$	
Loss on debt extinguishment		_	_		_	0.75	0.01
Loss on investment ^{'8}		_	_		_	0.03	0.06
Other '9		_	0.03	0	.01	0.04	(0.02)
Other income tax matters 1.		_	_		_	(0.04)	_
Adjusted diluted earnings per share from continuing operations	\$	8.94 \$	6.02	\$ 13	.56 \$	9.42 \$	6.39

3DJ 69, &47G; I H) DCHDA? 7I; : +1C7C9?/A3I7I; B; CIH7H-&A; L ?> I>; 5/3/3; 9J CI? H7C; *M9>7C=;) DB B ?HDC/

^{7.} If II Z 9DCHH;: D<! ZL;; @H9DB E7G: L?>!I L;; @H?C!>; 9DB E7G'8A E; GD: HEGH Q;:/

^{* 2;} EG H CHADH HDCDJG70K HB; Cl *C) 7HE; G3A; E*,C9Y L >?9> L 7HCDI 9DG ID DJG9DC17CI*C= DE; G/12DCH*C; HDA I >1H2K HB; Cl *C-0JG> FJ7G; GI fil fV

⁹ 11>: G7: BHJ CG A71:: ID 91 GG CI E: GD: DE: G7/D0H CDC: D<L>?9> L: G CC: 3C? J7/NHP=C297C/

^{2;} EGH CH8; C, 4H-40B I>; GHD4H2DCD<9; 677C 2C9DB; I7MB 7H; 6HJCG AFI; : ID 9JGG CI E; CD: DE; C7L*DCH*</p>





3DJ G9, &47G=; I`H) DCHDR 7I; : +1C7C97/A3I7I; B; CIH7H-4A: L 1> I>; 5/3/3; 9J CIP; H7C: *M>7C=;) DB B 1HDC/

^{3 2;} EGH CH = 710H fMDH HDC DIGOK HB; Cl (C) 7HE; G3A; E', C9Y L > 2> L 7HCDI 9DG ID DIG9DCl(C) 7C= DE; G1/DCl(F) HDA I> HDA I> HDK HB; Cl (C-DIG> FJ70; GI fil fV

^{9 11&}gt;; G1; BHJ CG ATI; : ID 9J CG CI E; CD: DE; CFI DCH CDC; DL > 79> L; G 1C: 1K? J 7/MIH=C2297C/

^{5- 2;} EG H CHB; C; ₹H-40B I>; G HD41/DC D<9; G7/C 2C9DB; 17/MB 7II; G-IJ CG; ATI;: ID 9J GG; CI E; CD: DE; CJ/DCH/